Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics Global (NASDAQ: PRE) has released its unaudited financial results for Q1 2024. The company reported a 30.2% increase in revenue to $6.4 million and a 159.8% rise in gross profit to $3.8 million compared to Q1 2023. Adjusted EBITDA improved by 55.9%, amounting to a loss of $4.1 million. Prenetics holds cash and short-term assets totaling $86.6 million. Insighta, a joint venture focused on early cancer detection, also had a cash balance of $79.8 million.
The company is strategically pivoting towards the U.S. consumer healthcare market, establishing dual headquarters in the U.S. and focusing on science-based health solutions. Insighta is progressing with promising pre-clinical data on prostate cancer and is set to commence a 1,500-person clinical trial in July 2024.
Prenetics Global (NASDAQ: PRE), a genomic-driven health sciences company, has partnered with MZ Group to lead a strategic investor relations and financial communications program. This collaboration aims to increase the company's visibility and communicate its technological advancements in health and wellness. Prenetics offers services like health-focused DNA tests, early cancer detection, and genomic profiling for targeted cancer therapy. With a strong cash position, no debt, and a dedicated management team, Prenetics is poised for growth and value creation for its shareholders. MZ Group, known for its expertise and global presence, will provide strategic counsel to Prenetics, enhancing market connections and communication strategies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Prenetics Global Limited (NASDAQ: PRE) announced its fourth quarter and full year 2022 financial results, reporting a revenue of US$275.8 million for 2022 and US$52.3 million for Q4 2022, reflecting a 19.2% decrease year-over-year. The Company achieved an adjusted EBITDA of US$58.3 million for 2022. Notably, Prenetics is shifting focus to precision oncology, highlighted by the acquisition of ACT Genomics, the first Asian firm to receive FDA clearance for its genomic profiling test. The Company aims to implement a US$20 million share buy-back program while also reducing its workforce by 60% to streamline operations and cut costs.